Journal of Clinical Oncology
Articles in this Issue
Phase 2 study of combined therapy FOLFOX with dabrafenib and cetuximab/panitumumab as first-line treatment for patients with metastatic colorectal cancer MSS with BRAF V600E mutation.
TPS248 Background: The standard of first line therapy for patients with metastatic BRAF V600E- mutated and MSS phenotype m...
Sarcopenia measured radiographically as a prognostic and predictive factor of response to perioperative FLOT regimen chemotherapy in gastric cancer patients.
447 Background: The response rate after neoadjuvant chemotherapy (NAC) in locally advanced GEJ cancer and GC patients rema...
Magnetic and indocyanine green (ICG) sentinel lymph node mapping in colorectal cancer: A feasibility and validity clinical trial.
31 Background: This is a single center, open label, side-by-side comparator study to assess the safety, feasibility and va...
GEMINI-Perioperative (PeriOp) Gastric: A phase 2 study of novel agent-based combinations as PeriOp therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
TPS469 Background: The standard-of-care treatment for resectable gastric cancer with a high risk of relapse is PeriOp FLOT...
A phase II study of enfortumab vedotin in patients with advanced or metastatic colorectal cancer or hepatocellular carcinoma.
TPS610 Background: Even with the advance of systemic therapy in gastrointestinal (GI) cancers over the past decade, the th...
Influence of the NECTIN2-TIGIT axis on resistance to PD-L1 blockade combined with chemoradiotherapy in MSS locally advanced rectal cancer.
188 Background: While PD-1/PD-L1 blockade combined with chemoradiotherapy benefits dMMR/MSI-H colorectal cancer (CRC) pati...
Disparities in pancreatic cancer burden across states, sex, and risk factors: A GBD 2021 study.
669 Background: Pancreatic cancer is among the most lethal gastrointestinal malignancies in the United States. Identifying...
Sociocultural and educational determinants of delayed diagnosis in anal cancer: Insights from a 5-year global social media analysis.
7 Background: Global incidence of squamous cell carcinoma of the anal canal (SCAC) is rising, despite preventability throu...
Tislelizumab plus chemoradiotherapy (CRT) versus CRT or chemotherapy (CT) as the neoadjuvant treatment for patients (pts) with locally advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A multicenter, randomized controlled, open-label, phase IIb study (TERRIFIC).
286 Background: MATTERHORN study has demonstrated that immunotherapy (IO) plus triple CT as neoadjuvant treatment signific...
A pilot study of atrovastatin +/- aspirin (ASA) chemoprevention in patients (pts) with Lynch Syndrome (LS): Recruitment, retention, adherence, and acceptability.
98 Background: Pts w/LS have high lifetime risk of colorectal cancer (CRC). Intensive colonoscopy surveillance is standard...
Real-world utilization of tissue-free ctDNA monitoring in patients with cholangiocarcinoma.
515 Background: Circulating tumor DNA (ctDNA) for assessing treatment response and resistance is being explored in clinica...
Optimizing and assessing the clinical effectiveness of deep-inspiration breath hold compared to free breathing in radiotherapy for gastric lymphoma.
416 Background: Variable anatomy, prompted by bowel filling and respiratory motion, necessitates larger margins for planni...
Treatment patterns in advanced gastric cancer (GC) across racial and ethnic groups in the immunotherapy era: A retrospective claims data analysis in the United States.
296 Background: Treatment for advanced GC has evolved in recent years, with anti-programmed cell death protein 1 (PD-1) im...
Innovative carbon-ion radiotherapy for unresectable pancreatic cancer using SIB and LET optimization: Results of a phase I dose-escalation trial.
723 Background: Carbon-ion radiotherapy (C-ion RT) for pancreatic cancer is commonly administered at an RBE-weighted dose...
Predictors of readmission and readmission-related mortality in older adults with pancreatic adenocarcinoma: Role of palliative care and discharge disposition.
788 Background: Patients with pancreatic adenocarcinoma are often faced with a multitude of symptoms. This often results i...
Real-world anti-EGFR therapy in elderly mCRC patients: A monocentric analysis stratified by comorbidity and polypharmacy.
67 Background: Elderly patients with metastatic colorectal cancer (mCRC) are increasingly encountered in clinical practice...
Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G/GEJ adenocarcinoma: Phase 3, double-blind, randomized trial (LUCERNA).
TPS473 Background: The anti-CLDN18.2 antibody zolbetuximab + first-line chemotherapy demonstrated longer progression-free...
Predictive biomarkers of systemic treatment in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis of randomized controlled trials.
770 Background: Pancreatic ductal adenocarcinoma (PDAC) is typically treated with unselected therapy. Biomarkers for respo...
Incidental gastric micro-GISTs in sleeve gastrectomy: Incidence and intraoperative management in a single-center cohort.
456 Background: Incidental gastrointestinal stromal tumors (GISTs) are increasingly recognized during bariatric surgery. T...
Comparison between nivolumab plus ipilimumab, FOLFOX and nivolumab plus FOLFOX therapy as first-line treatment for cisplatin-unfit advanced esophageal squamous cell carcinoma.
388 Background: Nivolumab plus platinum-based chemotherapy and nivolumab plus ipilimumab (Nivo+Ipi) therapy are standard f...
Adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (RICE): A prospective, phase 2 trial.
314 Background: The prognosis for locally advanced esophageal squamous cell carcinoma (LAESCC) remains poor.This study aim...
Biomarker prevalence in US patients with gastric/gastroesophageal junction adenocarcinoma (GEA) from real-world data.
444 Background: The therapeutic landscape for gastric (GA)/ gastroesophageal junction (GEJ) adenocarcinoma (GEA) has advan...
Phase I-II trial of perioperative chemotherapy plus atezolizumab and tiragolumab in localized esophageal and gastroesophageal junction adenocarcinoma.
418 Background: Management of esophageal and gastroesophageal junction (GEJ) adenocarcinoma focuses on perioperative strat...
Pancreatic cancer and coexisting diabetes: Survival outcomes from a provincial Canadian cohort.
674 Background: Diabetes mellitus (DM) is both a risk factor for and a potential consequence of pancreatic ductal adenocar...
Clinicopathological and mutational factors related to survival in patients with gastrointestinal stromal tumors in the American British Cowdray Medical Center in Mexico City.
852 Background: Gastrointestinal stromal tumors (GIST) account for approximately 0.1–3% of all gastrointestinal neoplasms....